Immunoregulatory therapy strategies that target cytokine storms in patients with COVID‑19 (Review)
- Authors:
- Xianyao Wang
- Zhixu He
- Xing Zhao
-
Affiliations: Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China, National Joint Local Engineering Laboratory for Cell Engineering and Biomedicine Technique, Guizhou Province Key Laboratory of Regenerative Medicine, Key Laboratory of Adult Stem Cell Translational Research, Chinese Academy of Medical Sciences, Guiyang, Guizhou 550004, P.R. China - Published online on: February 3, 2021 https://doi.org/10.3892/etm.2021.9750
- Article Number: 319
This article is mentioned in:
Abstract
|
Lum LHW and Tambyah PA: Outbreak of COVID-19 - an urgent need for good science to silence our fears? Singapore Med J. 61:55–57. 2020.PubMed/NCBI View Article : Google Scholar | |
|
World Health Organization: WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/. Accessed August 30, 2020. | |
|
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al: Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 382:1199–1207. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Tsatsakis A, Calina D, Falzone L, Petrakis D, Mitrut R, Siokas V, Pennisi M, Lanza G, Libra M, Doukas SG, et al: SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem Toxicol. 146(111769)2020.PubMed/NCBI View Article : Google Scholar | |
|
Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, Nitulescu G, Ion GND, Spandidos DA, Nikolouzakis TK, Drakoulis N and Tsatsakis A: Comprehensive analysis of drugs to treat SARS CoV 2 infection: Mechanistic insights into current COVID 19 therapies (Review). Int J Mol Med. 46:467–488. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ruscitti P, Berardicurti O, Iagnocco A and Giacomelli R: Cytokine storm syndrome in severe COVID-19. Autoimmun Rev. 19(102562)2020.PubMed/NCBI View Article : Google Scholar | |
|
Napp LC and Bauersachs J: Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome. Shock. 54:700–701. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, et al: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 584:450–456. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Satarker S and Nampoothiri M: Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2. Arch Med Res. 51:482–491. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 395:507–513. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 323:1061–1069. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wan Y, Shang J, Graham R, Baric RS and Li F: Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 94:e00127–e20. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, et al: Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 77:683–690. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W and Hao P: Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 63:457–460. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Mangalmurti N and Hunter CA: Cytokine Storms: Understanding COVID-19. Immunity. 53:19–25. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Lin SH, Zhao YS, Zhou DX, Zhou FC and Xu F: Coronavirus disease 2019 (COVID-19): Cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome. Genes Dis. 7:520–527. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Xu J, Zhong S, Liu J, Li L, Li Y, Wu X, Li Z, Deng P, Zhang J, Zhong N, et al: Detection of severe acute respiratory syndrome coronavirus in the brain: Potential role of the chemokine mig in pathogenesis. Clin Infect Dis. 41:1089–1096. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, et al: Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 136:95–103. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM and Suliman BA: MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 104:8–13. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Neurath MF: COVID-19 and immunomodulation in IBD. Gut. 69:1335–1342. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sapan HB, Paturusi I, Jusuf I, Patellongi I, Massi MN, Pusponegoro AD, Arief SK, Labeda I, Islam AA, Rendy L, et al: Pattern of cytokine (IL-6 and IL-10) level as inflammation and anti-inflammation mediator of multiple organ dysfunction syndrome (MODS) in polytrauma. Int J Burns Trauma. 6:37–43. 2016.PubMed/NCBI | |
|
Kang YJ, Jeung IC, Park A, Park YJ, Jung H, Kim TD, Lee HG, Choi I and Yoon SR: An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression. Hum Reprod. 29:2176–2189. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Wang C, Fei D, Li X, Zhao M and Yu K: IL-6 may be a good biomarker for earlier detection of COVID-19 progression. Intensive Care Med. 46:1475–1476. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Crisafulli S, Isgrò V, La Corte L, Atzeni F and Trifirò G: Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. BioDrugs. 34:415–422. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Velasco Puyo P, Moreno L, Diaz de Heredia C, Riviere JG and Soler Palacin P: Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome. An Pediatr (Engl Ed). 93:132–133. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Qian S, An J, Qi F, Ye L, Chen Q, Liu X, Xie L and Li G: Tocilizumab exerts anti-inflammatory activity in six critically ill COVID-19 patients: A retrospective analysis. Ann Transl Med. 8(881)2020.PubMed/NCBI View Article : Google Scholar | |
|
Tanaka T, Narazaki M and Kishimoto T: Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 8:959–970. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT and Pazdur R: FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 23:943–947. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, Cao X, Liu J, Yang Y, Wang B, et al: Management of cytokine release syndrome related to CAR-T cell therapy. Front Med. 13:610–617. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Faguer S, Vergez F, Peres M, Ferrandiz I, Casemayou A, Belliere J, Cointault O, Lavayssiere L, Nogier MB, Prevot G, et al: Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis. Hematol Oncol. 34:55–57. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Luo P, Liu Y, Qiu L, Liu X, Liu D and Li J: Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 92:814–818. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, et al: Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 117:10970–10975. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Carey B and Trapnell BC: The molecular basis of pulmonary alveolar proteinosis. Clin Immunol. 135:223–235. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Sever-Chroneos Z, Murthy A, Davis J, Florence JM, Kurdowska A, Krupa A, Tichelaar JW, White MR, Hartshorn KL, Kobzik L, et al: GM-CSF modulates pulmonary resistance to influenza A infection. Antiviral Res. 92:319–328. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Damiani G, McCormick TS, Leal LO and Ghannoum MA: Recombinant human granulocyte macrophage-colony stimulating factor expressed in yeast (sargramostim): A potential ally to combat serious infections. Clin Immunol. 210(108292)2020.PubMed/NCBI View Article : Google Scholar | |
|
Li SF, Gong MJ, Zhao FR, Shao JJ, Xie YL, Zhang YG and Chang HY: Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection. Cell Physiol Biochem. 51:2377–2396. 2018.PubMed/NCBI View Article : Google Scholar | |
|
González-Navajas JM, Lee J, David M and Raz E: Immunomodulatory functions of type I interferons. Nat Rev Immunol. 12:125–135. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, Qiu F, Wang X, Zou X, Wan D, et al: Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host Microbe. 28:455–464.e2. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chu H, Chan JF, Wang Y, Yuen TT, Chai Y, Hou Y, Shuai H, Yang D, Hu B, Huang X, et al: Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: An ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 71:1400–1409. 2020.PubMed/NCBI View Article : Google Scholar | |
|
O'Brien TR, Thomas DL, Jackson SS, Prokunina-Olsson L, Donnelly RP and Hartmann R: Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19. Clin Infect Dis. 71:1410–1412. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N and Suganuma N: Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci. 76:3323–3348. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Enciso N, Avedillo L, Fermín ML, Fragío C and Tejero C: Regenerative potential of allogeneic adipose tissue-derived mesenchymal cells in canine cutaneous wounds. Acta Vet Scand. 62(13)2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang X, Wang H, Lu J, Feng Z, Liu Z, Song H, Wang H, Zhou Y and Xu J: Erythropoietin-Modified Mesenchymal Stem Cells Enhance Anti-fibrosis Efficacy in Mouse Liver Fibrosis Model. Tissue Eng Regen Med. 17:683–693. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Baharlou R, Rashidi N, Ahmadi-Vasmehjani A, Khoubyari M, Sheikh M and Erfanian S: Immunomodulatory Effects of Human Adipose Tissue-derived Mesenchymal Stem Cells on T Cell Subsets in Patients with Rheumatoid Arthritis. Iran J Allergy Asthma Immunol. 18:114–119. 2019.PubMed/NCBI | |
|
Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, et al: Human mesenchymal stem cells modulate B-cell functions. Blood. 107:367–372. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Luz-Crawford P, Kurte M, Bravo-Alegría J, Contreras R, Nova-Lamperti E, Tejedor G, Noël D, Jorgensen C, Figueroa F, Djouad F, et al: Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther. 4(65)2013.PubMed/NCBI View Article : Google Scholar | |
|
Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Fu QL and Lian Q: Mesenchymal stem cells and immunomodulation: Current status and future prospects. Cell Death Dis. 7(e2062)2016.PubMed/NCBI View Article : Google Scholar | |
|
Elgaz S, Kuçi Z, Kuçi S, Bönig H and Bader P: Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease. Transfus Med Hemother. 46:27–34. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Kamal MM and Kassem DH: Therapeutic Potential of Wharton's Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges. Front Cell Dev Biol. 8(16)2020.PubMed/NCBI View Article : Google Scholar | |
|
Yang JH, Liu FX, Wang JH, Cheng M, Wang SF and Xu DH: Mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles: Potential roles in rheumatic diseases. World J Stem Cells. 12:688–705. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Radmanesh F, Mahmoudi M, Yazdanpanah E, Keyvani V, Kia N, Nikpoor AR, Zafari P and Esmaeili SA: The immunomodulatory effects of mesenchymal stromal cell-based therapy in human and animal models of systemic lupus erythematosus. IUBMB Life. 72:2366–2381. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Fu Y, Ni J, Chen J, Ma G, Zhao M, Zhu S, Shi T, Zhu J, Huang Z, Zhang J, et al: Dual-Functionalized MSCs that Express CX3CR1 and IL-25 Exhibit Enhanced Therapeutic Effects on Inflammatory Bowel Disease. Mol Ther. 28:1214–1228. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Regmi S, Pathak S, Kim JO, Yong CS and Jeong JH: Mesenchymal stem cell therapy for the treatment of inflammatory diseases: Challenges, opportunities, and future perspectives. Eur J Cell Biol. 98(151041)2019.PubMed/NCBI View Article : Google Scholar | |
|
Wang XY: MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment. Eur Rev Med Pharmacol Sci. 24:4537–4538. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Karaöz E and Tepeköy F: Differentiation Potential and Tumorigenic Risk of Rat Bone Marrow Stem Cells Are Affected By Long-Term In Vitro Expansion. Turk J Haematol. 36:255–265. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Shao C, Tian G, Huang Y, Liang W, Zheng H, Wei J, Wei C, Yang C, Wang H and Zeng W: Thymosin alpha-1-transformed Bifidobacterium promotes T cell proliferation and maturation in mice by oral administration. Int Immunopharmacol. 15:646–653. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Hsia J, Sarin N, Oliver JH and Goldstein AL: Aspirin and thymosin increase interleukin-2 and interferon-gamma production by human peripheral blood lymphocytes. Immunopharmacology. 17:167–173. 1989.PubMed/NCBI View Article : Google Scholar | |
|
Wu X, Jia J and You H: Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opin Biol Ther. 15 (Suppl 1):S129–S132. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Goldstein AL, Zatz MM, Low TL and Jacobs R: Potential role of thymosin in the treatment of autoimmune diseases. Ann N Y Acad Sci. 377 (1 Myasthenia Gr):486–495. 1981.PubMed/NCBI View Article : Google Scholar | |
|
Ioannou K, Samara P, Livaniou E, Derhovanessian E and Tsitsilonis OE: Prothymosin alpha: A ubiquitous polypeptide with potential use in cancer diagnosis and therapy. Cancer Immunol Immunother. 61:599–614. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al: Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 8:420–422. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wand S, Klages M, Kirbach C, Warszawska J, Meybohm P, Zacharowski K and Koch A: IgM-Enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis: A Before-After Cohort Study. PLoS One. 11(e0160907)2016.PubMed/NCBI View Article : Google Scholar | |
|
Alejandria MM, Lansang MA, Dans LF and Mantaring JB III: Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013(CD001090)2013.PubMed/NCBI View Article : Google Scholar | |
|
Cao W, Liu X, Bai T, Fan H, Hong K, Song H, Han Y, Lin L, Ruan L and Li T: High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infect Dis. 7(ofaa102)2020.PubMed/NCBI View Article : Google Scholar | |
|
Stegmayr B, Ramlow W and Balogun RA: Beyond dialysis: Current and emerging blood purification techniques. Semin Dial. 25:207–213. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Luo S, Yang L, Wang C, Liu C and Li D: Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab. Zhejiang Da Xue Xue Bao Yi Xue Ban. 49:227–231. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese). | |
|
Zuccari S, Damiani E, Domizi R, Scorcella C, D'Arezzo M, Carsetti A, Pantanetti S, Vannicola S, Casarotta E, Ranghino A, et al: Changes in Cytokines, Haemodynamics and Microcirculation in Patients with Sepsis/Septic Shock Undergoing Continuous Renal Replacement Therapy and Blood Purification with CytoSorb. Blood Purif. 49:107–113. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Jiménez-Brítez G, Ruiz P and Soler X: Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience. Med Clin (Barc). 155:410–411. 2020.PubMed/NCBI View Article : Google Scholar : (In En, Spanish). | |
|
Lockey RF and Hudey SN: Coronavirus disease 2019-associated urticaria with angioedema in a morbidly obese man successfully treated with glucocorticoids. Ann Allergy Asthma Immunol. 125:359–360. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhao R, Wang H, Wang X and Feng F: Steroid therapy and the risk of osteonecrosis in SARS patients: A dose-response meta-analysis. Osteoporos Int. 28:1027–1034. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, et al: Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 116:76–84. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 181:271–280.e8. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ramsey ML, Nuttall J and Hart PA: TACTIC Investigative Team. A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: Study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC). Trials. 20(501)2019.PubMed/NCBI View Article : Google Scholar | |
|
Hong X, Xiong J, Feng Z and Shi Y: Extracorporeal membrane oxygenation (ECMO): Does it have a role in the treatment of severe COVID-19? Int J Infect Dis. 94:78–80. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, MacLaren G, Brodie D and Shekar K: Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 8:518–526. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Cho HJ, Heinsar S, Jeong IS, Shekar K, Li Bassi G, Jung JS, Suen JY and Fraser JF: ECMO use in COVID-19: Lessons from past respiratory virus outbreaks-a narrative review. Crit Care. 24(301)2020.PubMed/NCBI View Article : Google Scholar | |
|
Atluri S, Manchikanti L and Hirsch JA: Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Pain Physician. 23:E71–E83. 2020.PubMed/NCBI | |
|
Tovar I, Guerrero R, López-Peñalver JJ, Expósito J and Ruiz de Almodóvar JM: Rationale for the Use of Radiation-Activated Mesenchymal Stromal/Stem Cells in Acute Respiratory Distress Syndrome. Cells. 9(E2015)2020.PubMed/NCBI View Article : Google Scholar | |
|
Kavianpour M, Saleh M and Verdi J: The role of mesenchymal stromal cells in immune modulation of COVID-19: Focus on cytokine storm. Stem Cell Res Ther. 11(404)2020.PubMed/NCBI View Article : Google Scholar |
